August 1 2020

Men who are carriers of a BRCA2 pathogenic variant were more likely to develop breast, prostate, and pancreatic cancers than patients harboring BRCA1, according to an analysis of male and female carriers of BRCA1/2 pathogenic variants.

According to the CDC, patients at any age who have cancer are at an increased risk of severe illness due to coronavirus disease 2019 (COVID-19), and this may be aggravated by aspects such as race, ethnicity, and socioeconomic factors.

Short and longterm safety and a meaningful reduction in worst pain were reported in patients with metastatic castration-resistant prostate cancer, based on results from the REASSURE trial.

“What we’re trying to do is move toward more personalized precision medicine based on what actually happens inside the tumor."

Much of the most important work that must be done during the development of a new cancer medication is often accomplished long after FDA approval, wrote Arjun V. Balar, MD.

As the new chair of the 17th Annual International Society of Gastrointestinal Oncology meeting, Tanios Bekaii-Saab, MD, said that this year’s virtual conference will place particular emphasis on fellows’ education and involvement.

Telemedicine increases efficiencies, supports coordinated care, and promotes flexibility in follow-up by allowing patients to be seen at any time and from any location.

Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.

Prostate-specific antigen changes were observed 6 weeks after the administration of 177Lu-PSMA in men with metastatic castration-resistant prostate cancer, suggesting a prognostic value for long-term clinical benefit, according to a single center retrospective analysis.